Oxford Ledge
Search
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a $6.0B biotechnology company trading at $44.81 (−2.1% today). Figures from SEC EDGAR and market feeds; updated 2026-09-04 21:32 UTC.
The company is a clinical-stage biopharmaceutical developer focused on treating brain health disorders using pharmaceutically optimized psychedelic and empathogen compounds. Its lead product candidate, DT120, a form of lysergide, is being developed for generalized anxiety disorder and major depressive disorder, with Phase 2b results published in a medical journal and FDA breakthrough designation granted for anxiety. The company is advancing DT120 into Phase 3 clinical trials with multiple studies in both anxiety and depression expected to produce results in 2026.
Summarized from Definium Therapeutics, Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $44.81 |
| Change (1D) | -0.98 (-2.15%) |
| Market cap | $6.0B |
| Volume | 898.4K shares |
| 52-week range | $44.81 – $45.79 |
| Returns | |
| 52-week return | +0.0% |
The company is a clinical-stage biopharmaceutical developer focused on treating brain health disorders using pharmaceutically optimized psychedelic and empathogen compounds.
DFTX trades at $44.81, as of 2026-09-04.
Definium Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-08-12. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-09-04 21:32 UTC. This page is also available as JSON at /api/data?ticker=DFTX and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for DFTX and 5,000+ tickers.
Create a free account — keep DFTXGET /api/data?ticker=DFTX
This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt